OW
SummitYüz yüzeGeçmiş etkinlik
2nd Obesity & Weight Loss Drug Development Summit Europe
Ev sahibi Hanson Wade
- 28 – 29 October 2026
- Hyperion Hotel München, Munich, Germany
- Health SciencesEczacılık ve Farmasötik BilimlerMedical & Health SciencesKlinik Tıp
Orada olacağınızı başkalarına bildirin. Bu işlem sizi etkinliğe kaydetmez.
kongre.net'e hoş geldiniz
kongre.net'e hoş geldiniz
Bildiri Çağrısı
Gönderimler kapandıGönderimler organizatör tarafından alınıyor
Gönderim bilgilerini görKayıt
Etkinlik sona erdiKayıt organizatör tarafından yapılıyor
Temel bilgiler
2nd Obesity & Weight Loss Drug Development Summit Europe, Hanson Wade tarafından 28 – 29 Ekim 2026 tarihlerinde Hyperion Hotel München, Munich, Almanya konumunda düzenlenen bir zirve etkinliğidir.
- Tarihler:
- 28 – 29 Ekim 2026
- Biçim:
- Yüz yüze
- Mekân:
- Hyperion Hotel München, Munich, Almanya
- Konular:
- Pharmacy & Pharmaceutical Sciences, Clinical Medicine
- Organizatör:
- Hanson Wade
- Resmi web sitesi:
- obesity-drug-development-europe.com
The 2nd Obesity & Weight Loss Drug Development Summit Europe is an industry-centred forum exploring new mechanisms of action, combination therapies, and tolerability improvements to define the next generation of obesity and weight loss therapeutics.
Konferans teması
Defining the Second Wave of Competitive & Efficacious Weight Loss Therapeutics
Hedefler
To engage with leading innovators and stakeholders to advance the next wave of obesity therapeutics beyond first-generation GLP-1s, uncover innovative targets, emerging combinations, and patient phenotyping approaches.
Kimler katılmalı
Drug developers, research organizations, and academic institutions.
Programdan öne çıkanlar
Programın tamamını görKonuşmacılar
20 konuşmacının tümünü görVP of Research & Development, Constructive Bio
Optimising Supply Chain & Manufacturing Strategies to Scale Obesity Therapeutics, Reduce Costs & Expand Patient AccessChief Scientific Officer, MitoRx Therapeutics Limited
Targeting Mitochondrially Unhealthy Obesity to Provide an Alternative Mode of Action for Obesity Therapeutics +1 dahaChief Executive & Scientific Officer, iBio
Unlocking Superior Obesity Outcomes by Preserving Muscle While Maximizing Fat LossPipeline & Commercialisation Strategy Head, Constructive Bio
Industry Leaders Fireside Chat: Driving Access, Therapeutic Advances & Scale to Position Europe as the Next Obesity Innovation HubTranslational Research Associate, Resalis Therapeutics
From Fat Selectivity to Rebound Prevention: Translating RES-010 from Target Discovery to Clinical DevelopmentFounder & Chief Scientific Officer, Cantoni Therapeutics
Harnessing Energy Expenditure Pathways to Improve Metabolic Health Beyond Appetite Suppression
Organizatör ve iletişim
İletişim
- Etkinlik sekreteryası:
- Darja Kielthy
- E-posta:
- [email protected]
Reklam
İlgili etkinlikler
- BIO-Europe 2026Cologne, Almanya9–11 Nov 2026
- ESMO AI & Digital Oncology Congress 2026Berlin, Almanya16–18 Nov 2026
- MEDICA 2026Düsseldorf, Almanya16–19 Nov 2026
- The Liver Meeting 2026Denver, Amerika Birleşik Devletleri5–9 Nov 2026
- WPATH Scientific Symposium 2026Mexico City, Meksika7–12 Nov 2026
- 6th World Congress on Global Healthcare and MedicineBangkok, Tayland9–10 Nov 2026